GLP‑1 real‑world data for obesity: A new standard for metabolic care
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
The therapeutic market that you know is shaped by the healthcare data that you can see. But when critical medical, specialty, clinical or longitudinal signals are absent from that view, the picture (and the decisions based on it) is less clear. ...
The rise of GLP-1 therapies and the evolution of obesity treatment Over 40% of adults in the U.S....
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
Turning claims into interoperable evidence More means more. In a world where anyone can make...
Thank you for visiting HealthVerity at Fierce 2025 HealthVerity had a fantastic week at Fierce...
At HealthVerity, community is at the heart of who we are. Each year, our team members come together...
AI agents are quickly becoming part of the clinical conversation. Since the release of large...
Digital health innovators and pharma leaders are under increasing pressure to show that new models...
Recently, Omada Health and HealthVerity announced a press release highlighting their collaboration...
(Part 2) In Part 1 we explored how HealthVerity Marketplace delivers high-quality,...
We put the newest HealthVerity eXOs capabilities to the test on one of the most-watched questions in healthcare: who is starting GLP-1s, where they are and what happens next. Here is what the new features did and what the data revealed.